New study data, on the basis of which the drug manufacturer applied for a new dossier assessment, were found by reviewers to be unsuitable: they not only compared two drugs, but also two therapeutic strategies.
New study data, on the basis of which the drug manufacturer applied for a new dossier assessment, were found by reviewers to be unsuitable: they not only compared two drugs, but also two therapeutic strategies.